Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Differential Tolerance to FTY720-induced Antinociception in Acute Thermal and Nerve Injury Mouse Pain Models: Role of S1P Receptor Adaptation.

Sim-Selley LJ, Wilkerson JL, Burston JJ, Hauser KF, McLane V, Welch SP, Lichtman AH, Selley DE.

J Pharmacol Exp Ther. 2018 Jun 26. pii: jpet.118.248260. doi: 10.1124/jpet.118.248260. [Epub ahead of print]

2.

Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?

Selley DE, Welch SP, Sim-Selley LJ.

Life Sci. 2013 Aug 14;93(5-6):187-93. doi: 10.1016/j.lfs.2013.06.004. Epub 2013 Jun 16. Review.

3.

Sphingosine-1-phosphate receptors as emerging targets for treatment of pain.

Welch SP, Sim-Selley LJ, Selley DE.

Biochem Pharmacol. 2012 Dec 15;84(12):1551-62. doi: 10.1016/j.bcp.2012.08.010. Epub 2012 Aug 16. Review.

PMID:
22971335
4.

Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at μ-opioid receptor-expressing glia.

Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE.

Brain. 2011 Dec;134(Pt 12):3616-31. doi: 10.1093/brain/awr281. Epub 2011 Nov 18.

5.

Sphingosine-1-phosphate receptors mediate neuromodulatory functions in the CNS.

Sim-Selley LJ, Goforth PB, Mba MU, Macdonald TL, Lynch KR, Milstien S, Spiegel S, Satin LS, Welch SP, Selley DE.

J Neurochem. 2009 Aug;110(4):1191-202. doi: 10.1111/j.1471-4159.2009.06202.x. Epub 2009 May 31.

6.

Interaction of the cannabinoid and opioid systems in the modulation of nociception.

Welch SP.

Int Rev Psychiatry. 2009 Apr;21(2):143-51. doi: 10.1080/09540260902782794. Review.

PMID:
19367508
7.

Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.

Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2008 Dec 14;600(1-3):50-8. doi: 10.1016/j.ejphar.2008.08.005. Epub 2008 Aug 20.

PMID:
18762181
8.

Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.

Williams J, Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2008 Apr 14;584(1):78-86. doi: 10.1016/j.ejphar.2007.12.035. Epub 2008 Feb 5.

PMID:
18313663
9.

The role of gonadal hormones on opioid receptor protein density in arthritic rats.

Kren MC, Haller VL, Welch SP.

Eur J Pharmacol. 2008 Jan 14;578(2-3):177-84. Epub 2007 Sep 11.

PMID:
18054782
10.

Chronic morphine treatment decreases the Cav1.3 subunit of the L-type calcium channel.

Haller VL, Bernstein MA, Welch SP.

Eur J Pharmacol. 2008 Jan 14;578(2-3):101-7. Epub 2007 Sep 11.

PMID:
18048029
11.

Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.

Smith PA, Selley DE, Sim-Selley LJ, Welch SP.

Eur J Pharmacol. 2007 Oct 1;571(2-3):129-37. Epub 2007 Jun 12.

12.

The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.

Cox ML, Haller VL, Welch SP.

Eur J Pharmacol. 2007 Sep 10;570(1-3):50-6. Epub 2007 Jun 5.

PMID:
17588560
13.

Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat.

Cox ML, Haller VL, Welch SP.

Eur J Pharmacol. 2007 Jul 12;567(1-2):125-30. Epub 2007 Apr 20.

PMID:
17498686
14.

Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.

Haller VL, Cichewicz DL, Welch SP.

Eur J Pharmacol. 2006 Sep 28;546(1-3):60-8. Epub 2006 Jul 25.

PMID:
16919265
15.

Fraud and abuse trends for 2006: what's hot for physicians and physician practices.

Daily AK, Welch SP.

J Med Pract Manage. 2006 May-Jun;21(6):319-22.

PMID:
16833059
16.

Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol.

Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, Welch SP.

Eur J Pharmacol. 2006 Jun 6;539(1-2):57-63. Epub 2006 Apr 6.

PMID:
16687136
17.

Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol.

Cichewicz DL, Welch SP, Smith FL.

Eur J Pharmacol. 2005 Nov 21;525(1-3):74-82. Epub 2005 Nov 8.

PMID:
16288738
18.

Mu and delta opioid-stimulated [35S]GTP gamma S binding in brain and spinal cord of polyarthritic rats.

Cichewicz DL, Cox ML, Welch SP, Selley DE, Sim-Selley LJ.

Eur J Pharmacol. 2004 Nov 3;504(1-2):33-8.

PMID:
15507218
19.

Reversal of delta 9-tetrahydrocannabinol-induced tolerance by specific kinase inhibitors.

Bass CE, Welch SP, Martin BR.

Eur J Pharmacol. 2004 Aug 2;496(1-3):99-108.

PMID:
15288581
20.

The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.

Cox ML, Welch SP.

Eur J Pharmacol. 2004 Jun 16;493(1-3):65-74.

PMID:
15189765
21.

The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.

Lee MC, Smith FL, Stevens DL, Welch SP.

J Pharmacol Exp Ther. 2003 May;305(2):593-9. Epub 2003 Feb 11.

22.
23.

Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors.

Smith FL, Javed R, Elzey MJ, Welch SP, Selley D, Sim-Selley L, Dewey WL.

Brain Res. 2002 Dec 20;958(1):28-35.

PMID:
12468027
24.
26.
27.
28.

Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.

Houser SJ, Eads M, Embrey JP, Welch SP.

Brain Res. 2000 Feb 28;857(1-2):337-42.

PMID:
10700588
29.

Synergistic interactions of endogenous opioids and cannabinoid systems.

Welch SP, Eads M.

Brain Res. 1999 Nov 27;848(1-2):183-90.

PMID:
10612710
30.

Antisenses to opioid receptors attenuate ATP-gated K(+) channel opener-induced antinociception.

Lohmann AB, Welch SP.

Eur J Pharmacol. 1999 Nov 19;384(2-3):147-52.

PMID:
10611434
31.
32.

A method for the determination of activated receptor phosphorylation state following in vivo drug treatment.

Bernstein MA, Welch SP.

Brain Res Brain Res Protoc. 1999 Dec;4(3):420-4.

PMID:
10592353
33.

A diminution of delta9-tetrahydrocannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development.

Mason DJ Jr, Lowe J, Welch SP.

Eur J Pharmacol. 1999 Sep 24;381(2-3):105-11.

PMID:
10554877
34.

Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.

Mason DJ Jr, Lowe J, Welch SP.

Eur J Pharmacol. 1999 Aug 13;378(3):237-48.

PMID:
10493099
35.

Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.

Cichewicz DL, Martin ZL, Smith FL, Welch SP.

J Pharmacol Exp Ther. 1999 May;289(2):859-67.

36.

Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.

Welch SP, Huffman JW, Lowe J.

J Pharmacol Exp Ther. 1998 Sep;286(3):1301-8.

37.
38.

The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol.

Smith FL, Cichewicz D, Martin ZL, Welch SP.

Pharmacol Biochem Behav. 1998 Jun;60(2):559-66.

PMID:
9632241
39.

Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.

Smith FL, Fujimori K, Lowe J, Welch SP.

Pharmacol Biochem Behav. 1998 May;60(1):183-91.

PMID:
9610941
40.

Inhibition of protein phosphatases alters the expression of morphine tolerance in mice.

Bernstein MA, Welch SP.

Eur J Pharmacol. 1998 Jan 12;341(2-3):173-7.

PMID:
9543237
41.

Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance.

Rowen DW, Embrey JP, Moore CH, Welch SP.

Pharmacol Biochem Behav. 1998 Feb;59(2):399-404.

PMID:
9476987
42.

Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.

Pugh G Jr, Mason DJ Jr, Combs V, Welch SP.

J Pharmacol Exp Ther. 1997 May;281(2):730-7.

43.

Morphine tolerance-induced modulation of [3H]glyburide binding to mouse brain and spinal cord.

Welch SP, Smith FL, Dewey WL.

Drug Alcohol Depend. 1997 Apr 14;45(1-2):47-53.

PMID:
9179506
45.
46.
47.

Characterization and modulation of acute tolerance to nicotine in mice.

Damaj MI, Welch SP, Martin BR.

J Pharmacol Exp Ther. 1996 Apr;277(1):454-61.

PMID:
8613954
48.
49.

Postpartum women in outpatient drug abuse treatment: correlates of retention/completion.

Strantz IH, Welch SP.

J Psychoactive Drugs. 1995 Oct-Dec;27(4):357-73.

PMID:
8788692
50.

Supplemental Content

Loading ...
Support Center